<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03748693</url>
  </required_header>
  <id_info>
    <org_study_id>HYMC-0073-18</org_study_id>
    <nct_id>NCT03748693</nct_id>
  </id_info>
  <brief_title>Inflammation and Cellular Immunity in Vaginal Tissue in Patients With Pelvic Organ Prolapse</brief_title>
  <official_title>Inflammation and Cellular Immunity in Vaginal Tissue in Patients With Pelvic Organ Prolapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hillel Yaffe Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hillel Yaffe Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the inflammatory and maturation processes of immature
      myeloid cells (IMC) in the vaginal tissue in women with advanced pelvic organ prolapse (POP)
      (stage III-IV) and in normal non-POP controls.

      We hypothesize that the processes contributing to POP may be related to immune response and
      changes in myeloid cell populations and the cytokine environment.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2018</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Immune response in POP</measure>
    <time_frame>Two weeks</time_frame>
    <description>Tissue biopsy will analyzed for IMC and compared to control group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cytokine environment in POP</measure>
    <time_frame>Two weeks</time_frame>
    <description>Tissue biopsy will analyzed for cytokine environment and compared to control group</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Pelvic Organ Prolapse</condition>
  <arm_group>
    <arm_group_label>POP Group</arm_group_label>
    <description>Women with POP undergoing surgery in our OB/GYN department.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-POP Group</arm_group_label>
    <description>Women undergoing hysterectomy for other indications.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hysterectomy</intervention_name>
    <description>Surgery performed on women with a variety of gynecological indications</description>
    <arm_group_label>Non-POP Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Colporrhaphy</intervention_name>
    <description>Surgery performed on women with POP</description>
    <arm_group_label>POP Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women attending our OB/GYN department because of POP and other gynecological disorders
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with POP undergoing colporrhaphy

          -  Women undergoing hysterectomy

        Exclusion Criteria:

          -  Autoimmune and connective tissue disorders

          -  Cancer in genital tract
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Mariana Ordonez, MD</last_name>
    <phone>972-52-3243474</phone>
    <email>malo_mariana@hotmail.com</email>
  </overall_contact>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 19, 2018</study_first_submitted>
  <study_first_submitted_qc>November 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2018</study_first_posted>
  <last_update_submitted>November 19, 2018</last_update_submitted>
  <last_update_submitted_qc>November 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Prolapse</mesh_term>
    <mesh_term>Pelvic Organ Prolapse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

